{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:55:30Z","timestamp":1780458930584,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glucocorticoids (GCs) are the main treatment of relapse in multiple sclerosis (MS). Decreased sensitivity to GCs in MS patients has been associated with lack of the suppressive effect of GCs on inflammatory molecules as well as increased resistance to apoptosis. We investigated GC-sensitivity by measuring the effect of intravenous methylprednisolone (IVMP) treatment on transactivation of anti-inflammatory and apoptotic genes (GILZ, MCL-1 and NOXA respectively), in accordance to clinical outcome. Thirty nine MS patients were studied: 15 with clinically isolated syndrome (CIS), 12 with relapsing remitting (RRMS) and 12 with secondary progressive (SPMS) under relapse. Patients underwent treatment with IVMP for 5\u00a0days. Blood was drawn before IVMP treatment on day 1 and 1\u00a0h after IVMP treatment on days 1 and 5. GIlZ, MCL-1 and NOXA were determined by qPCR. The Expanded Disability Status was evaluated and patients were divided according to their clinical response to IVMP. GILZ and MCL-1 gene expression were significantly higher following first IVMP treatment in responders, compared to non-responders. Furthermore, serum basal cortisol and 1,25-OH Vitamin D levels were significantly higher in clinical-responders as compared to non-clinical responders. Our findings suggest that the differential GILZ and MCL-1 gene expression between clinical-responders and non-clinical responders may implicate the importance of GILZ and MCL-1 as possible markers for predicting glucocorticoid sensitivity and response to GC-therapy in MS patients following first IVMP injection.<\/jats:p>","DOI":"10.1038\/s41598-021-98868-y","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:30:41Z","timestamp":1632997841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response"],"prefix":"10.1038","volume":"11","author":[{"given":"Maria Eleftheria","family":"Evangelopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjes","family":"Nasiri-Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios Stergios","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Moutsatsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"98868_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","volume":"11","author":"JS Sloka","year":"2005","unstructured":"Sloka, J. S. & Stefanelli, M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11, 425\u2013432 (2005).","journal-title":"Mult. Scler."},{"key":"98868_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.psyneuen.2014.03.012","volume":"45","author":"T K\u00fcmpfel","year":"2014","unstructured":"K\u00fcmpfel, T. et al. Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis. Psychoneuroendocrinology 45, 87\u201395 (2014).","journal-title":"Psychoneuroendocrinology"},{"key":"98868_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2013.09.007","volume":"132","author":"RH Oakley","year":"2013","unstructured":"Oakley, R. H. & Cidlowski, J. A. The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease. J. Allergy Clin. Immunol. 132, 1033\u20131044 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"98868_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","volume":"182","author":"LK Smith","year":"2010","unstructured":"Smith, L. K. & Cidlowski, J. A. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog. Brain Res. 182, 1\u201330 (2010).","journal-title":"Prog. Brain Res."},{"key":"98868_CR5","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1038\/cddis.2012.193","volume":"4","author":"I Wu","year":"2013","unstructured":"Wu, I. et al. Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes. Cell Death Dis. 4, e453 (2013).","journal-title":"Cell Death Dis."},{"key":"98868_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1212\/WNL.53.4.772","volume":"53","author":"FT Bergh","year":"1999","unstructured":"Bergh, F. T., K\u00fcmpfel, T., Trenkwalder, C., Rupprecht, R. & Holsboer, F. Dysregulation of the hypothalamopituitary-adrenal axis is related to the clinical course of MS. Neurology 53, 772\u2013777 (1999).","journal-title":"Neurology"},{"key":"98868_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jneuroim.2005.04.014","volume":"165","author":"SM Gold","year":"2005","unstructured":"Gold, S. M. et al. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J. Neuroimmunol. 165, 186\u2013191 (2005).","journal-title":"J. Neuroimmunol."},{"key":"98868_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4530(01)00071-3","volume":"27","author":"C Heesen","year":"2002","unstructured":"Heesen, C., Gold, S. M., Raji, A., Wiedemann, K. & Schulz, K. H. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 27, 505\u2013517 (2002).","journal-title":"Psychoneuroendocrinology"},{"key":"98868_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jneuroim.2004.02.009","volume":"151","author":"RH DeRijk","year":"2004","unstructured":"DeRijk, R. H., Eskandari, F. & Sternberg, E. M. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J. Neuroimmunol. 151, 180\u2013188 (2004).","journal-title":"J. Neuroimmunol."},{"key":"98868_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/1352458509359721","volume":"16","author":"LML Van Winsen","year":"2010","unstructured":"Van Winsen, L. M. L., Polman, C. H., Dijkstra, C. D., Tilders, F. J. H. & Uitdehaag, B. M. J. Suppressive effect of glucocorticoids on TNF-\u03b1 production is associated with their clinical effect in multiple sclerosis. Mult. Scler. 16, 500\u2013502 (2010).","journal-title":"Mult. Scler."},{"key":"98868_CR11","doi-asserted-by":"publisher","first-page":"E1402","DOI":"10.1210\/jc.2012-1294","volume":"97","author":"SM Gold","year":"2012","unstructured":"Gold, S. M. et al. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. J. Clin. Endocrinol. Metab. 97, E1402 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"98868_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jneuroim.2014.07.004","volume":"276","author":"L Bechmann","year":"2014","unstructured":"Bechmann, L. et al. Corticosteroid receptor expression and in vivo glucocorticoid sensitivity in multiple sclerosis. J. Neuroimmunol. 276, 159\u2013165 (2014).","journal-title":"J. Neuroimmunol."},{"key":"98868_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/annrheumdis-2015-207744","volume":"75","author":"SA Jones","year":"2016","unstructured":"Jones, S. A. et al. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Ann. Rheum. Dis. 75, 739\u2013747 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"98868_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.33.11.1444","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology https:\/\/doi.org\/10.1212\/wnl.33.11.1444 (1983).","journal-title":"Neurology"},{"key":"98868_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032","author":"WI McDonald","year":"2001","unstructured":"McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.1032 (2001).","journal-title":"Ann. Neurol."},{"key":"98868_CR16","doi-asserted-by":"crossref","unstructured":"Ayroldi, E. & Riccardi, C. Glucocorticoid\u2010induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 23, 3649\u20133658 (2009).","DOI":"10.1096\/fj.09-134684"},{"key":"98868_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02018-8","author":"R Hoepner","year":"2019","unstructured":"Hoepner, R. et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-019-02018-8 (2019).","journal-title":"Acta Neuropathol."},{"key":"98868_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121\u2013127 (2001).","journal-title":"Ann. Neurol."},{"key":"98868_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33, 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"98868_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"98868_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. Determinaci\u00f3n de prote\u00ednas: M\u00e9todo de bradford. Anal. Biochem. 72, 248 (1976).","journal-title":"Anal. Biochem."},{"key":"98868_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2281-3","author":"E Kassi","year":"2016","unstructured":"Kassi, E. et al. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cell. Mol. Life Sci. https:\/\/doi.org\/10.1007\/s00018-016-2281-3 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"98868_CR23","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1002\/elps.200600207","volume":"27","author":"M Weinkauf","year":"2006","unstructured":"Weinkauf, M., Hiddemann, W. & Dreyling, M. Sample pooling in 2-D gel electrophoresis: A new approach to reduce nonspecific expression background. Electrophoresis 27, 4555\u20134558 (2006).","journal-title":"Electrophoresis"},{"key":"98868_CR24","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1096\/fj.09-134684","volume":"23","author":"E Ayroldi","year":"2009","unstructured":"Ayroldi, E. & Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): A new important mediator of glucocorticoid action. FASEB J. 23, 3649\u20133658 (2009).","journal-title":"FASEB J."},{"key":"98868_CR25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-134684","author":"E Ayroldi","year":"2009","unstructured":"Ayroldi, E. & Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): A new important mediator of glucocorticoid action. FASEB J. https:\/\/doi.org\/10.1096\/fj.09-134684 (2009).","journal-title":"FASEB J."},{"key":"98868_CR26","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3389\/fimmu.2019.01684","volume":"10","author":"JK Flynn","year":"2019","unstructured":"Flynn, J. K., Dankers, W. & Morand, E. F. Could GILZ be the answer to glucocorticoid toxicity in lupus?. Front. Immunol. 10, 1684 (2019).","journal-title":"Front. Immunol."},{"key":"98868_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/tpj.2016.71","volume":"18","author":"C De Andres","year":"2018","unstructured":"De Andres, C. et al. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: Potential biomarkers. Pharmacogenomics J. 18, 98\u2013105 (2018).","journal-title":"Pharmacogenomics J."},{"key":"98868_CR28","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1212\/01.wnl.0000336918.32695.6b","volume":"71","author":"MC Ysrraelit","year":"2008","unstructured":"Ysrraelit, M. C., Gait\u00e1n, M. I., Lopez, A. S. & Correale, J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 71, 1948\u20131954 (2008).","journal-title":"Neurology"},{"key":"98868_CR29","doi-asserted-by":"publisher","first-page":"e60647","DOI":"10.1371\/journal.pone.0060647","volume":"8","author":"S Kern","year":"2013","unstructured":"Kern, S. et al. Cortisol awakening response is linked to disease course and progression in multiple sclerosis. PLoS ONE 8, e60647 (2013).","journal-title":"PLoS ONE"},{"key":"98868_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mce.2008.10.011","volume":"298","author":"BA Burkhart","year":"2009","unstructured":"Burkhart, B. A., Ivey, M. L. & Archer, T. K. Long-term low level glucocorticoid exposure induces persistent repression in chromatin. Mol. Cell. Endocrinol. 298, 66\u201375 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"98868_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1001\/archneur.58.1.91","volume":"58","author":"VI Leussink","year":"2001","unstructured":"Leussink, V. I., Jung, S., Merschdorf, U., Toyka, K. V. & Gold, R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58, 91\u201397 (2001).","journal-title":"Arch. Neurol."},{"key":"98868_CR32","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/1352458508090666","volume":"14","author":"M Matysiak","year":"2008","unstructured":"Matysiak, M., Makosa, B., Walczak, A. & Selmaj, K. Patients with multiple sclerosis resisted to glucocorticoid therapy: Abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult. Scler. 14, 919\u2013926 (2008).","journal-title":"Mult. Scler."},{"key":"98868_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington, E. M. et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 24, 878\u2013888 (2017).","journal-title":"Cell Death Differ."}],"updated-by":[{"DOI":"10.1038\/s41598-021-02415-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98868-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98868-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98868-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:02:26Z","timestamp":1670083346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98868-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98868"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98868-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-02415-8","URL":"https:\/\/doi.org\/10.1038\/s41598-021-02415-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19462"}}